Publication Detail

Citation : Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. (2014)
Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for...
J Neurovirol 20(6):571-82.
Abstract : HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30-50%) despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART). There is no proven therapy for individuals on suppressive cART with HAND. We have shown that the degree of HIV reservoir burden (HIV DNA) in monocytes appear to be linked to cognitive outcomes. HIV infection of monocytes may therefore be critical in the pathogenesis of HAND. A single arm, open-labeled trial was conducted to examine the effect of maraviroc (MVC) intensification on monocyte inflammation and neuropsychological (NP) performance in 15 HIV subjects on stable 6-month cART with undetectable plasma HIV RNA (<48 copies/ml) and detectable monocyte HIV DNA (>10 copies/10(6) cells). MVC was added to their existing cART regimen for 24 weeks. Post-intensification change in monocytes was assessed using multiparametric flow cytometry, monocyte HIV DNA content by PCR, soluble CD163 (sCD163) by an ELISA, and NP performance over 24 weeks. In 12 evaluable subjects, MVC intensification resulted in a decreased proportion of circulating intermediate (median; 3.06% (1.93, 6.45) to 1.05% (0.77, 2.26)) and nonclassical (5.2% (3.8, 7.9) to 3.2% (1.8, 4.8)) CD16-expressing monocytes, a reduction in monocyte HIV DNA content to zero log10 copies/10(6) cells and in levels of sCD163 of 43% by 24 weeks. This was associated with significant improvement in NP performance among six subjects who entered the study with evidence of mild to moderate cognitive impairment. The results of this study suggest that antiretroviral therapy with potency against monocytes may have efficacy against HAND.
URL Link : http://www.ncbi.nlm.nih.gov/pubmed/25227930
PMID : 25227930
PMCID : PMC4268390
News
15 September 2017:
RCMI Conference Travel Support

We are currently encouraging scientists engaged in health disparities research, healthcare and public health professionals, public policy professional…

10 September 2017:
Call for Abstracts: RCMI Translational Science 2017 Conference

Call for Abstracts

Abstract Deadline Extended

Submit Your Abstracts

Abstract submission for oral and poster presentations is…

16 May 2017:
Robert Wood Johnson Funding Opportunity

If our nation is to make the opportunity for health available to all, we need leaders who will be able to meet the challenges before us – leade…


View more news...


Seminars & Events
16 June 2017, 9am - 10:30am:
HEALTH & MEDICINE SEMINAR - Kukulu Ola Hou
02 June 2017, 8:15am - 4:10pm:
PROMOTING EXCELLENCE IN CLINICAL RESEARCH
02 November 2016, 9am:
RMATRIX-II Collaboration Pilot Projects Program 2017 -- Informational Webinar

View more seminars & events...

Supported by a grant from the National Institute on Minority Health and Health Disparities (U54MD007584), National Institutes of Health.